ey0015.4-3 | Important for clinical practice | ESPEYB15
M van der Steen
, GF Kerkhof
, CCJ Smeets
, ACS Hokken-Koelega
To read the full abstract: Lancet Diabetes Endocrinol 2017;5:975-985Whereas most SGA children experience spontaneous catch-up growth leading to the achievement of normal adult height, approximately 10% remain short and are candidates for GH therapy. SGA subjects have increased cardio-metabolic disease risk [17] and the effects of GH treatment on blood...